{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013047","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.650316+00:00","generated_at":"2026-06-12T08:31:20.426956+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Voyager Q2 net loss $22.2M, launches anti-Aβ gene therapy for Alzheimer's","bullets":["Q2 2023 collaboration revenue $4.9M (up from $0.7M YoY); net loss $22.2M vs $19.1M YoY.","Cash, equivalents and marketable securities $272.7M as of June 30, 2023; funding into 2025.","New vectorized anti-Aβ antibody gene therapy research initiative for Alzheimer's disease launched.","Executed license agreement with Sangamo for prion disease treatment using TRACER capsid.","VY-TAU01 anti-tau antibody IND on track for H1 2024; GLP tox studies to start in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013047","json":"https://secwatch.observer/filing/0001558370-23-013047.json","markdown":"https://secwatch.observer/filing/0001558370-23-013047.md","text":"https://secwatch.observer/filing/0001558370-23-013047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837023013047/0001558370-23-013047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837023013047/vygr-20230803x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:31:20.426956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d906370f37b5a67fe953ea94d16d820c7da5571","claim":"Voyager Therapeutics, Inc. reported the six months ended June 30, 2023 results: revenue $155.3 million, net income Net income was $101.8 million.","evidence_excerpt":"Voyager had collaboration revenue of $155.3 million for the six months ended June 30, 2023 period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000155837023013047/0001558370-23-013047-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Revenue","value":"$155.3 million"},{"label":"Net income","value":"Net income was $101.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"94bf82e8b5e0711c604c2671ac35418284850fc0","claim":"Voyager Therapeutics, Inc. reported the second quarter of 2023 results: revenue $4.9 million, net income Net loss was $22.2 million.","evidence_excerpt":"Voyager had collaboration revenue of $4.9 million for the second quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000155837023013047/0001558370-23-013047-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$4.9 million"},{"label":"Net income","value":"Net loss was $22.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}